Related Experiment Video

Updated: Sep 21, 2025

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
08:41

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

2.9K

Pharmacologic Treatment and Management of Coronavirus Disease 2019

Amy Hirsch Shumaker1, Adarsh Bhimraj2

  • 1Clinical Pharmacy Specialist-Infectious Disease, Department of Pharmacy, VA Northeast Ohio Healthcare System, 10701 East Boulevard, Pharmacy 119 (W), Cleveland, OH 44106, USA; Senior Clinical Instructor, School of Medicine, Case Western Reserve University, 10900 Euclid Ave, Cleveland, OH 44106-7341.

Infectious Disease Clinics of North America
|May 31, 2022
PubMed

Insights

Significant progress has been made in COVID-19 pharmacotherapy through randomized controlled trials. Emerging oral antiviral treatments offer growing optimism for managing coronavirus disease 2019.

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Clinical Medicine

Background:

  • Understanding of pharmacotherapy for coronavirus disease 2019 (COVID-19) has advanced over the past two years.
  • Numerous randomized controlled trials have evaluated novel and repurposed treatments.

Purpose of the Study:

  • To summarize the progress in COVID-19 pharmacotherapy.
  • To highlight the importance of updated treatment guidelines for clinicians.

Main Methods:

  • Review of large- and small-scale randomized controlled trials.
  • Analysis of clinical evidence for various COVID-19 treatments.

Main Results:

  • Several treatments have shown benefits in reducing mortality and hospitalization.
  • Oral antiviral treatments for COVID-19 are demonstrating promising results.

Conclusions:

  • Clinicians must stay informed about the evolving landscape of COVID-19 treatments.
  • Patient management should consider individual illness severity and location, guided by current evidence and guidelines.
Keywords:
AntiviralsBaricitinibCOVID-19CorticosteroidsMonoclonal antibodiesSARS CoV-2Tocilizumab

More Related Videos

Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses03:53

Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses

Published on: November 10, 2023

1.4K
Nasal Brushing Sampling and Processing Using Digital High Speed Ciliary Videomicroscopy – Adaptation for the COVID-19 Pandemic09:03

Nasal Brushing Sampling and Processing Using Digital High Speed Ciliary Videomicroscopy – Adaptation for the COVID-19 Pandemic

Published on: November 7, 2020

5.0K

Related Concept Videos

Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
463
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
2.7K
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
351
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
37
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
90
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
24